20 Future Dutch HealthTech and MedTech Leaders

Nelson Advisors
2 hours ago
15 min read

The Dutch healthcare technology and medical technology landscape entering 2026 stands at a profound inflection point, characterised by a definitive transition from the speculative fragmentation of the early 2020s toward a disciplined era of industrial maturity.

Following a period of structural recalibration in 2024 and a tentative recovery in 2025, the market is currently experiencing a robust, albeit structurally transformed, resurgence in capital deployment and mergers and acquisitions. The defining thesis for 2026 is the concept of "Industrialisation," which signifies a departure from the "growth at all costs" paradigm that defined the Zero Interest Rate Policy era. In this current cycle, the cost of capital remains elevated, forcing a rigorous recalibration of investment criteria toward unit economics and measurable clinical impact.

The Netherlands has positioned itself as a top-tier hub for innovation, yet it faces a rapidly changing global environment where ambition alone is no longer sufficient to maintain a leading position. Deeptech remains the Dutch ecosystem's powerhouse, producing 41% of all scaleups and attracting the majority of venture capital in 2025.

However, a significant "AI Paradox" persists; despite having the highest density of AI talent in Europe, the Dutch conversion rate of AI startups to scaleup status is only a quarter of the rate seen in the United States. This gap is a primary focus of national strategic initiatives aimed at securing the country's long-term growth through 2035.

Strategic Foundations and the National Growth Plan

The Dutch MedTech sector has unveiled an ambitious national growth plan designed to position the Netherlands at the summit of the European medical technology hierarchy by 2035. This plan, developed with contributions from academic hospitals, universities, knowledge institutions, and the business community, addresses two strategic interests simultaneously: the creation of a future-proof healthcare system and the development of a resilient, innovative economy.

The targets for this initiative are substantial, aiming to generate approximately €5 Billion in additional annual export value and foster the arrival of around 75 new startups and scale-ups.

Strategic Indicator	2026 Projection / Target	Contextual Benchmark
Per Capita Health Expenditure	$7,200	Up from $6,490 in 2021
National MedTech Job Creation	$11,000 new high-quality roles	Engineering, R&D and production
Projected Annual Export Growth	€5 Billion	Strategic economic contribution
AI Talent Density	10.9% per 10,000 inhabitants	Highest in Europe
Scaleup Conversion Ratio	21.6%	Lagging behind European average of 24.1%

The pressure on the healthcare system, driven by an aging population and a lagging number of healthcare providers, has made technological innovation a necessity for maintaining accessible and affordable care. Corporate leaders, such as Royal Philips CEO Roy Jakobs, emphasise that investing in medical technology is a matter of strategic clout within Europe.

The 2026 market is no longer interested in generic digital health applications; instead, smart capital is flowing into the "unsexy" backend infrastructure of healthcare, the data plumbing that enables interoperability between fragmented systems.

The Regulatory Crucible: Darwinism in the EU AI Act Era

In 2026, regulation has evolved from a compliance requirement into the primary determinant of asset value and investability. The market is undergoing a phenomenon described as "Regulatory Darwinism," where only those entities capable of navigating the increasingly complex EU and UK regulatory landscapes will survive and command premium valuations.

A critical milestone in this shift is the full enforcement of the EU AI Act for "High-Risk" systems beginning in March 2026. This act serves as a binary filter for HealthTech AI investment, requiring medical AI tools to meet stringent requirements for data governance, human oversight and transparency.

Furthermore, the transition to the Medical Device Regulation and the In Vitro Diagnostic Regulation has created a "compliance moat". Large strategic acquirers are now engaging in "compliance-driven M&A," targeting smaller competitors not merely for their technological innovation but to secure their existing regulatory approvals, which now serve as significant financial assets in themselves.

The difficulty of obtaining these certifications has led to a market bifurcation where compliant assets command a 20-30% premium, while non-compliant assets face an 18–24 month regulatory bottleneck and subsequent valuation compression.

The M&A and Investment Horizon in 2026

The M&A landscape in 2026 is characterised by a "Selective Recovery" and a "flight to quality". While total deal value in the MedTech sector surged to $97.6 Billion in 2025, the highest level in over a decade, overall deal activity has remained selective.

Corporate venture activity has become a critical pillar of the ecosystem, with incumbents like Philips, Medtronic, and Siemens Healthineers using their venture arms as strategic reconnaissance tools to secure early stakes in scalable innovations across AI, robotics and precision diagnostics.

Segment	EV / Revenue Multiple	EV / EBITDA Multiple	Key Valuation Drivers
Premium AI & Data Platforms	6.0x – 12.0x+	15x – 20x+	Proprietary datasets; Rule of 40 performance
Value-Based Care (VBC)	5.5x – 7.5x	12x – 15x	ROI for payers; high population health impact
General HealthTech SaaS	4.0x – 6.0x	10x – 13x	Predictable unit economics; stable retention
MedTech / Hardware	3.5x – 5.5x	11x – 14x	MDR/IVDR compliance; high barriers to entry
Sub-scale / Unprofitable	2.5x – 4.0x	N/A	High burn; lack of clear defensibility

A significant financial vector shaping 2026 is the unprecedented accumulation of unallocated capital, with global private equity funds holding nearly $2.5 Trillion in "dry powder". This capital is increasingly focused on high-quality assets with defensible technology and repeatable revenue. Exits are primarily being driven by strategic acquirers looking for proven technology to future-proof their businesses against structural shifts in care delivery and patient demographics.

High-Growth MedTech & HealthTech Companies in Holland

The following twenty companies represent the most significant entities to watch in the Dutch ecosystem, each uniquely positioned for growth, fundraising, or acquisition based on their technological defensibility, clinical validation, and strategic alignment with 2026 market trends.

1. Onward Medical: Restoring Movement through NeuroTechnology

Onward Medical, headquartered in Eindhoven with a presence in Switzerland and the US, is a leader in neurotechnology therapies designed to restore movement and independence for individuals with spinal cord injuries. The company’s proprietary ARC Therapy has been awarded 10 Breakthrough Device Designations by the FDA, a testament to its clinical significance. In early 2026, Onward reported the completion of seven human implants of its ARC-BCI system, which pairs a brain-computer interface with implantable spinal cord stimulation to restore thought-driven movement.

The company recently raised $50.85 Million in a private placement to fund product development and the expansion of its sales and operations. Onward has successfully transitioned to a commercial-stage company, seeing robust demand for its ARC-EX system in the US and Europe. Its technology is frequently compared to Elon Musk’s Neuralink, yet Onward’s established clinical results and regulatory clearances position it as a primary contender for leadership in the neuro-stimulation market.

2. Salvia Bioelectronics: Minimally Invasive Migraine Treatment

Based in Eindhoven, Salvia Bioelectronics focuses on treating chronic migraine through thin, bioelectronic foils that adapt to the anatomy of the head. These ultra-thin implants target key nerves involved in migraine, emitting gentle electrical impulses to reduce the hypersensitivity of the nervous system. Salvia’s solution addressed a massive unmet need for millions of people for whom traditional pharmacologic therapy has failed.

In 2025, Salvia closed a successful $60 Million Series B funding round led by Innovation Industries and supported by the European Innovation Council Fund. This funding is being used to complete clinical development, including the multi-centre, double-blind RECLAIM study and prepare for commercial launch in the US, Europe, and Australia. Having received FDA Breakthrough Device status in 2020, Salvia is positioned for a significant valuation as it nears market authorisation.

3. Vitestro: Pioneering Autonomous Robotic Phlebotomy

Utrecht-based Vitestro is redefining one of the largest and most under-innovated clinical workflows: diagnostic blood collection. Their Aletta Autonomous Robotic Phlebotomy Device (ARPD) integrates advanced robotics, multimodal imaging, and AI to autonomously identify suitable veins and perform blood draws. In March 2026, Vitestro announced the close of a $70 Million Series B round, which included strategic investment from US healthcare leaders such as Labcorp Venture Fund, Mayo Clinic and Sutter Health.

This investment underscores the strong conviction in Vitestro's mission to establish a new standard in venous access, addressing critical healthcare challenges such as staffing shortages and human-dependent variability. The device is already CE-marked and being deployed in Europe, with the new funding fueling its US FDA De Novo regulatory pathway and global commercial readiness. Vitestro's technology met its primary endpoint in clinical studies with a $95\%$ first-stick success rate, comparable to the most skilled human practitioners.

4. ViCentra: Redefining Diabetes Care with Kaleido

ViCentra, based in Utrecht, develops the Kaleido insulin patch pump system, designed to minimize the impact of diabetes on daily life. Kaleido is notable for being the smallest, lightest, and most precise insulin patch pump in its class, designed with the form and function of a lifestyle product rather than a traditional medical device. In January 2026, ViCentra expanded its Series D financing to a total of $98 Million, supported by Novo Holdings and a consortium of Dutch investors.

The company doubled its European user base to over 4,000 in 2025 and is using the new capital to scale manufacturing and accelerate preparations for US market access. In a competitive insulin pump market, ViCentra’s focus on empathetic innovation and customisable aesthetics, offering shells in ten vibrant colours, serves as a strong differentiator that appeals to users seeking both glycemic control and personal expression.

5. Azafaros: Rare Disease Therapies for Lysosomal Storage Disorders

Leiden-based Azafaros is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for rare genetic disorders. Their lead asset, nizubaglustat, is a small molecule azasugar designed to treat neurological symptoms in lysosomal storage disorders like GM1/GM2 gangliosidoses and Niemann-Pick disease Type C.Nizubaglustat has received numerous regulatory designations, including FDA Fast Track and Orphan Drug status in the US and Europe.

In May 2025, Azafaros secured $132 Million in an oversubscribed Series B round, one of the largest for a Dutch biotech company, to advance its Phase 3 clinical programs. The company is currently recruiting for global Phase 3 studies, with catalysts expected in 2026 as more data from these pivotal trials becomes available. Its strong investor syndicate, including Forbion and BioGeneration Ventures, positions it as a high-potential target for acquisition by large pharmaceutical companies looking to bolster their rare disease portfolios.

6. Healthplus.ai: Predicting Post-Surgery Complications

Amsterdam-based Healthplus.ai utilizes AI to predict the risk of postoperative infections, enabling clinical teams to intervene proactively. Their CE-certified system, PERISCOPE, re-uses existing electronic health record data to provide predictive insights without requiring additional actions from healthcare professionals. In late 2025, the startup raised $2.3 Million to further accelerate the rollout of its AI system in Europe and the US.

The investment round was led by Elevating Capital and LUMO Labs, and the funds will be used to pursue FDA clearance and deep integration with major EHR platforms like Epic, Cerner and ChipSoft. Healthplus.ai’s focus on clinical validation and regulatory certification allows it to bridge the gap between medical AI innovation and everyday hospital practice, reducing hospital costs and shortening patient recovery times.

7. Aiosyn: Transforming Pathology with AI

Aiosyn, a spin-off from Radboudumc in Nijmegen, develops AI software that accelerates histopathological diagnostics.Their algorithms automate complex diagnostic tasks, empowering pathologists to deliver faster and more consistent results for cancer and kidney disease patients. In September 2025, Aiosyn’s mitotic figure counting algorithm became the first AI-powered mitosis detection solution to achieve CE marking under the In Vitro Diagnostic Regulation.

Studies have shown that pathologists using Aiosyn's software achieved up to 60% time savings per slide and a 32.6% improvement in consistency. The company recently secured $2.4 Million in funding and entered a strategic partnership with TNO to accelerate the clinical validation and market readiness of its AI diagnostic solutions.

8. AMT Medical: Robotic Heart Bypass Surgery

AMT Medical, based in Ede, has raised $25 Million in Series B funding to transform heart bypass surgery. Their ELANA system connects graft vessels to coronary arteries through small incisions using a mechanical clip and laser, eliminating the need for open-chest access. The system is designed for robotic compatibility and aims to make bypass surgery safer and faster, potentially enabling same-day discharge. With funding secured to complete European trials and expand into the US, AMT Medical is poised to "rewrite the future of cardiovascular care" by making traditional open-heart bypass obsolete.

9. ScreenPoint Medical: Leader in Breast AI

Nijmegen-based ScreenPoint Medical is a world leader in machine learning for breast imaging. Their market-leading software, Transpara, assists radiologists in reading 2D and 3D mammograms, significantly improving the early detection of breast cancer. As medical imaging enters the era of "Intelligence Amplification," ScreenPoint’s software serves as a critical workflow tool, addressing the growing global shortage of specialised radiologists while enhancing diagnostic accuracy.

10. Sirius Medical: Non-Radioactive Tumor Localisation

Sirius Medical, a spin-off from the Netherlands Cancer Institute, provides advanced tumor localization technology. Their Pintuition system offers a non-radioactive alternative for surgeons to precisely locate tumors during procedures, particularly in breast cancer treatment. By improving surgical precision and workflow efficiency, Sirius Medical has gained significant traction in the market, positioning it as an attractive acquisition target for larger surgical technology companies focused on curative medtech.

11. Onera Health: At-Home Sleep Diagnostics

Eindhoven-based Onera Health is transforming sleep medicine with its wearable, medical-grade diagnostic patch. The Onera system allows patients to undergo professional sleep studies at home, monitoring vitals and sleep quality without the need for a traditional sleep lab. Backed by over €30 Million in funding and numerous design awards, Onera is poised to set a new standard for home-based sleep testing by 2026, addressing the estimated 1 in 5 people who struggle with sleep disorders.

12. Thirona: Precision AI for Lung Imaging

Thirona utilizes AI to analyse lung CT scans with high precision, helping medical specialists quantify abnormalities and monitor disease progression. Their technology is used by pharmaceutical and medtech companies to assess drug efficacy and support personalised surgical interventions. As lung cancer screening programs expand across Europe and the US, Thirona’s ability to objectively quantify very detailed abnormalities makes it a vital partner in the respiratory care ecosystem.

13. Microsure: Robotics for Microsurgery

Microsure develops MUSA, the world’s first clinically available robotic system for open microsurgery. The system allows surgeons to perform reconstructive and vascular procedures with extreme precision by filtering out hand tremors. Microsure’s technology addresses complex surgical challenges that are beyond the reach of traditional robotic systems, positioning it at the forefront of the next generation of surgical robotics.

14. Leyden Labs: Intranasal Protection against Viruses

Leiden Labs focuses on developing intranasal medicines that target viruses at the port of entry, the nose and throat. Their mission is to provide immediate, broad-spectrum protection against respiratory viruses through "chemical masks" like their lead candidate, CR9114. With significant backing from Google Ventures and SoftBank, Leyden Labs represents a paradigm shift in biodefense and preventive medicine, offering an alternative to traditional vaccines that require time to build immunity.

15. Ellogon AI: Accelerating Immunotherapy

Ellogon AI develops AI tools that help pharmaceutical companies analyze complex biomedical data and accelerate drug discovery, specifically in the field of immunotherapy. Their focus on identifying immune cell infiltration patterns in cancer tissue enables more personalized treatment plans for oncology patients. In an era where biopharma companies are facing patent cliffs, Ellogon’s ability to optimise patient selection for clinical trials provides massive economic value.

16. Incision: Digital Assistant for Surgical Teams

Incision is a rapidly expanding platform that provides online training and team alignment for surgical professionals. Their mobile app facilitates visual learning and preparation, empowering surgical teams to improve outcomes through better team coordination and standardised training. As healthcare systems prioritise efficiency and quality benchmarking, Incision’s platform addresses the global need for continuous professional development in the operating room.

17. Pacmed: ICU Decision Support

Pacmed utilises machine learning to predict the risk of readmission and discharge for individual Intensive Care Unit patients. Their product, Pacmed Critical, uses data from tens of thousands of patients to support clinical decision-making, ensuring that patients are discharged only when it is safe to do so. This predictive capability reduces the strain on intensive care resources and improves long-term patient outcomes.

18. Kepler Vision Technologies: Monitoring the Elderly

Kepler Vision uses computer vision-enabled monitoring to identify if elderly patients have fallen or are in discomfort.Their Night Nurse solution analyses live video streams and can distinguish between true emergencies and false alarms, such as blankets moving. This technology is essential for addressing the staffing shortages in elderly care facilities, providing 24/7 monitoring that preserves patient dignity while ensuring safety.

19. Inbiome: Rapid Bacterial Diagnosis

Inbiome’s "Molecular Culture" technology provides rapid DNA-based tests that can diagnose bacterial infections in under four hours. This is a significant improvement over traditional culture techniques that take days or weeks. Faster diagnosis allows for the prompt administration of the correct antibiotics, reducing the risk of complications and stopping the further transmission of infections.

20. Nicolab: Saving Time in Stroke Care

Nicolab’s StrokeViewer combines AI with a cloud environment to instantly detect strokes on medical scans and send alerts to physicians' mobile devices. Because "time is brain" in stroke care, Nicolab’s ability to shorten the time to treatment significantly improves the chances of a full recovery for patients. Their platform is a prime example of how digital health can bridge the gap between hospital diagnostics and rapid intervention.

Regional Clusters and Growth Ecosystems

The success of these companies is deeply rooted in the specialised regional clusters across the Netherlands, each offering unique infrastructure and talent pools that support the move toward industrial maturity in 2026.

Brainport Eindhoven: The High-Tech Engine

Eindhoven remains a center for leading technology and healthcare innovation, particularly for companies focused on robotics, electronics engineering, and neurotechnology. The proximity to technical universities and a strong base in semiconductors and photonics has birthed giants like Onward Medical and Salvia Bioelectronics. The region is characterised by active recruitment for electronics engineers and product development specialists, reflecting its role as the hardware and systems engineering hub of the Dutch MedTech sector.

Leiden Bio Science Park: The Biotech Frontier

Leiden is the primary hub for biotechnology and life sciences, hosting clinical-stage firms like Azafaros and Leyden Labs.The announcement of Eli Lilly's new $3 Billion manufacturing facility in Leiden has further solidified the region's global standing. This facility, planned to begin construction in 2026, will produce oral medicines, including next-generation GLP-1 therapies, and is expected to create 500 high-skilled manufacturing jobs. Leiden’s ecosystem benefits from a dense concentration of research institutes and proximity to key European regulatory bodies.

Utrecht Science Park: Digital Health and MedTech Scaling

Utrecht has emerged as a location for high-growth MedTech companies like Vitestro and ViCentra. The region's focus on clinical validation and scaling manufacturing is supported by regional investment funds like ROM Utrecht Region, which participated in the recent funding rounds for both companies. Utrecht is seeing high demand for Regulatory Affairs specialists and Quality Assurance directors, as companies there transition from innovation-led startups to commercially active scale-ups.

Strategic M&A Drivers: The Role of Incumbents and Private Equity

In 2026, mergers and acquisitions are driven by a shift toward fewer but much larger, high-value transactions. Strategic acquirers are prioritising proven technology and category leadership over speculative growth.

Medtronic’s Strategic Footprint in the Netherlands

Medtronic remains a dominant force in the Dutch ecosystem, not only through its operational headquarters but also through its aggressive acquisition strategy. In February 2026, Medtronic announced its intent to exercise its option to acquire CathWorks, a deal valued at up to $585 Million. This acquisition bolsters Medtronic’s interventional cardiology portfolio by integrating CathWorks’ AI-driven system for diagnosing and treating coronary artery disease.

Medtronic’s strategy highlights several 2026 trends:

Expanding into high-growth procedural segments like cardiovascular and neurostimulation.
Leveraging data and AI to deliver innovative solutions that assist physicians throughout the patient journey.
Divesting non-core or subscale assets to concentrate capital on differentiated technologies.

Private Equity's Pragmatic Pivot

Private equity sponsors are playing an expanding role in 2026, moving beyond traditional platform acquisitions toward "build-to-buy" constructs. Sponsors are increasingly focused on companies with durable cash flows and operational improvement opportunities. In the Dutch market, private equity participation is expected to increase as valuation gaps continue to narrow and firms deploy their substantial dry powder.

The "Rule of 40" has become the standard model for valuation, where the sum of a company's growth rate and profit margin must exceed $40\%$ to command premium multiples. This disciplined approach favours Dutch companies like ViCentra and Vitestro, which have demonstrated robust adoption and operational performance.

Conclusion: The Activation Phase of Dutch HealthTech

Entering the second half of 2026, the Dutch HealthTech and MedTech sectors have moved from the capital investment phase into the "activation phase". This is a moment where projects move from plans to performance, facilities move from construction to commissioning, and talent requirements ramp up significantly. The transition to "Industrial Maturity" has filtered out speculative ventures, leaving a core of twenty high-potential companies that are setting new global standards in robotics, neuro-technology and AI-driven diagnostics.

The Netherlands has successfully leveraged its academic knowledge and regional high-tech clusters to build a MedTech ecosystem that is not only future-proof but also structurally central to the European economy. For professional peers and investors, the strategic focus should remain on these high-quality assets that have navigated "Regulatory Darwinism" and are now positioned for global commercial adoption. As the EU AI Act enforcement reshapes the digital health landscape, the Dutch companies that have already secured their "compliance moats" will remain the most sought-after targets for the remainder of the 2026 deal cycle and beyond.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech